Kronox Lab Sciences financials

·ChemicalsChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹28.4cr+16.9% on Q1 FY26
Net profit
₹7.3cr+16.3% on Q1 FY26
EBITDA margin
31.7%−1.1 pts on Q1 FY26
EPS
₹2.00+17.6% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue28.424.3+16.9%
EBITDA9.08.0+12.9%
EBITDA margin31.7%32.8%−1.1 pts
Profit before tax9.88.4+16.2%
Net profit7.36.3+16.3%
EPS₹2.00₹1.70+17.6%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹28.4 crNet profit₹7.3 crNet margin25.7%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024
723———
2.72.73.02.6
1.61.60.00.0
721———
10510110089.9
—+1.0%+11.5%—
35.234.333.128.3
33.4%33.9%33.1%31.5%
33.132.231.727.0
28.627.725.321.4
27.1%27.3%25.3%23.8%
₹7.70₹7.45₹6.82₹5.75
—+9.3%+18.5%—
—23.932.517.4
—−3.3−3.1−12.3
20.620.629.45.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

KRONOX₹194.73

Kronox Lab Sciences Limited

· Chemicals
₹ CrorePeersJAYAGROGNDMCCSRHHYPOLTDCHEMFABPRIMOPLASTIBLENGEMAROMASUDARCOLORMcap ₹723 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization———722.5
- Cash, Equiv & ST Investments2.63.02.72.7
+ Total Debt0.00.01.61.6
Enterprise Value———721.4
Revenue89.9100.2101.2105.3
Growth %, YoY—+11.5+1.0—
EBITDA28.333.134.335.2
Margin %31.5133.0633.8633.41
EBIT27.031.732.233.1
Net Income21.425.327.728.6
Margin %23.7625.2627.3327.13
EPS, Adj (current shares)5.756.827.457.70
Growth %, YoY—+18.5+9.3—
Cash from Operations17.432.523.9—
Capital Expenditures-12.3-3.1-3.3—
Free Cash Flow5.129.420.620.6
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Kronox Lab Sciences financials and key ratios

Prices at the previous close · figures from the company's filings with NSE

Kronox Lab Sciences (NSE: KRONOX) had a market capitalisation of ₹723 crore at the previous close (₹194.73 a share), a PE ratio of 25.3 on the last four quarters' profit and a price-to-book ratio of 6.22. In FY26 its consolidated net profit was ₹27.7 crore on revenue of ₹101 crore; in Q1 FY27 (April–June 2026) it was ₹7.3 crore, up 16.3% year on year. Its debt-to-equity ratio was 0.01 on 31 March 2026. Promoters held 64.26% of the shares on 30 September 2026.

Share price used
₹194.73 · previous close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Kronox Lab Sciences at a glance · consolidated

Market cap
₹723 Crat ₹194.73 · previous close
PE ratio (last 4 quarters)
25.326.1 on FY26 profit
Price to book (PB)
6.22book value ₹31.30 a share
ROE (FY26)
26.8%−5.5 pts vs FY25ROCE 29.9%
Debt to equity
0.01net cash ₹47.1 Cr
Promoter holding
64.26%−9.9 pts vs 30 Jun 202630 September 2026
Dividend yield
0.26%₹0.50 a share in 12 months
Net worth
₹116 Cr+28.9% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹20.6 Cr−29.9% vs FY25

Questions

What is the Kronox Lab Sciences PE ratio today?

Kronox Lab Sciences' PE ratio is 25.3 at the previous close (₹194.73 a share): a market capitalisation of ₹723 crore divided by consolidated net profit of ₹28.6 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹27.7 crore) it is 26.1.

What is the Kronox Lab Sciences PB ratio (price to book value)?

Kronox Lab Sciences' price-to-book (PB) ratio is 6.22 at the previous close: a market capitalisation of ₹723 crore divided by shareholders' equity (book value) of ₹116 crore on 31 March 2026. That is a book value of ₹31.30 per share against a share price of ₹194.73.

What is the Kronox Lab Sciences book value per share?

Kronox Lab Sciences' book value per share was ₹31.30 on 31 March 2026: shareholders' equity of ₹116 crore divided by the 3.71 crore shares in issue, up 28.9% from ₹24.28 a year earlier. The share price at the previous close was ₹194.73.

What is the Kronox Lab Sciences market cap?

Kronox Lab Sciences' market capitalisation was ₹723 crore at the previous close: 3.71 crore shares at ₹194.73 each.

What is the Kronox Lab Sciences EPS?

Kronox Lab Sciences' basic earnings per share (EPS) were ₹7.51 in FY26, against ₹6.91 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹7.79.

What is the Kronox Lab Sciences dividend in 2026 and its record date?

In 2026, Kronox Lab Sciences has declared one dividend: ₹0.50 with record date 9 September 2026.

Is Kronox Lab Sciences debt free?

No. Kronox Lab Sciences had borrowings of ₹1.6 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.01. Its cash and current investments were ₹48.7 crore, so it held net cash of ₹47.1 crore.

What is the Kronox Lab Sciences debt to equity ratio?

Kronox Lab Sciences' debt-to-equity ratio was 0.01 on 31 March 2026: borrowings of ₹1.6 crore against total equity of ₹116 crore. A year earlier, on 31 March 2025, it was 0.00.

What is the Kronox Lab Sciences net worth?

Kronox Lab Sciences' net worth — shareholders' equity in its consolidated balance sheet — was ₹116 crore on 31 March 2026, up 28.9% from ₹90.1 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹723 crore at the previous close.

What is the Kronox Lab Sciences ROE and ROCE?

In FY26, Kronox Lab Sciences' return on equity (ROE) was 26.8% and its return on capital employed (ROCE) was 29.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 32.4% and ROCE 38.6%.

What is the Kronox Lab Sciences dividend yield?

Kronox Lab Sciences' dividend yield is 0.26% at the previous close: dividends of ₹0.50 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹194.73. They were ₹0.50 on 9 September 2026.

What is the Kronox Lab Sciences promoter holding?

Promoters held 64.26% of Kronox Lab Sciences on 30 September 2026, down 9.95 percentage points from 74.21% the previous quarter and down 9.95 percentage points from 74.21% a year earlier, according to the shareholding pattern filed with NSE.

What is the Kronox Lab Sciences shareholding pattern?

On 30 September 2026, Kronox Lab Sciences' shares were held by promoters 64.26%, foreign portfolio investors (FII/FPI) 0.10%, domestic institutions (DII) 2.54% and retail and other non-institutional investors 33.10%. Over the year, FII holding was up 0.07 percentage points from 0.03% and DII holding was up 0.61 percentage points from 1.93%.

What is the Kronox Lab Sciences free cash flow?

In FY26, Kronox Lab Sciences generated ₹23.9 crore of cash from operations and spent ₹3.3 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹20.6 crore. In FY25 it was ₹29.4 crore.

Kronox Lab Sciences vs Jayant Agro Organics: how do they compare?

In FY26, Kronox Lab Sciences earned net profit of ₹27.7 crore on revenue of ₹101 crore, against ₹50.4 crore on ₹2,406 crore for Jayant Agro Organics. Kronox Lab Sciences' operating margin was 31.8% (Jayant Agro Organics 3.4%) and its return on equity 26.8% (Jayant Agro Organics 8.5%).

What are the Kronox Lab Sciences latest quarterly results?

Kronox Lab Sciences' latest results are for Q1 FY27 (April–June 2026), filed on 12 August 2026: consolidated net profit ₹7.3 crore, up 16.3% from ₹6.3 crore in Q1 FY26; revenue from operations ₹28.4 crore, up 16.9% year on year.

What is the Kronox Lab Sciences revenue and profit in FY26?

In FY26 (April 2025–March 2026), Kronox Lab Sciences' consolidated net profit was ₹27.7 crore, up 9.3% from ₹25.3 crore in FY25, on revenue from operations of ₹101 crore (up 1.0%).

When are the Kronox Lab Sciences next results?

Kronox Lab Sciences has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.

How does Kronox Lab Sciences compare with its peers?

On FY26 consolidated figures, against Jayant Agro Organics, DMCC SPECIALITY CHEMICALS and Sree Rayalaseema Hi-Strength Hypo: Kronox Lab Sciences' operating margin of 31.8% is the highest of the four (Jayant Agro Organics 3.4%, DMCC SPECIALITY CHEMICALS 8.2%, Sree Rayalaseema Hi-Strength Hypo 12.2%; peer average 7.9%); its return on equity of 26.8% is the highest of the four (Jayant Agro Organics 8.5%, DMCC SPECIALITY CHEMICALS 11.5%, Sree Rayalaseema Hi-Strength Hypo 9.5%; peer average 9.8%).

Where do these Kronox Lab Sciences figures come from?

From Kronox Lab Sciences' own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.